NEW YORK, NY / ACCESSWIRE / June 15, 2015 / BELLUS Health Inc. (BLU.TO) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Roberto Bellini. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In today's blog, Mr. Bellini shares key takeaways from his attendance at the World Orphan Drug Conference that took place April 23rd and 24th, 2015. He discusses specifically the roles entrepreneurs, patients and players can play in the evolving rare disease field. Read the full blog post from Mr. Bellini on TheChairmansBlog.com (http://www.thechairmansblog.com/bellus-health-inc/roberto-bellini/temperature-running-hot-at-the-world-orphan-drug-conference).
About Bellus Health Inc.
BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIACTA(TM) in Phase III for AA amyloidosis, KIACTA(TM) for sarcoidosis, clinical stage Shigamab(TM) for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA(TM) is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. KIACTA(TM) is partnered with global private equity firm Auven Therapeutics.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.